Abstract | PURPOSE: PATIENTS AND METHODS: Patients with previously untreated ED-SCLC were enrolled in this trial. In the first, third and fifth cycles, PI (P: 60 mg/m(2) on day 1; I: 60 mg/m(2)/day on days 1, 8 and 15) was administered, whereas ACE (A: 50 mg/m(2) on day 1; C: 750 mg/m(2) on day 1; E 80 mg/m(2)/day on days 1-3) was given in the second, fourth and sixth cycles. Each cycle was repeated every 4 weeks. At the end of six cycles, patients who had obtained a complete response were given prophylactic cranial irradiation. RESULTS: In total, 28 patients were enrolled, of whom 27 were assessable for efficacy and safety. Objective responses, including 4 (15%) complete responses, were observed in 25 patients (93%). Median survival time was 12.9 months. The principal toxicity was myelosuppression; grade 4 neutropenia and thrombocytopenia were observed in 89 and 4%, respectively. Febrile neutropenia occurred in 30% of patients. Diarrhea was mild (grade 3-4; 4%). All toxicities were reversible and there were no treatment-related deaths. The mean percentage of the delivered doses, relative to the projected doses, of PI and ACE were 84.6 and 91.1%, respectively. CONCLUSIONS: These results indicate the PI- ACE regimen to have promising activity against ED-SCLC with moderate toxicities.
|
Authors | Masahiro Tabata, Katsuyuki Kiura, Niro Okimoto, Yoshihiko Segawa, Tetsu Shinkai, Toshiro Yonei, Shoichi Kuyama, Shingo Harita, Katsuyuki Hotta, Hiroshi Ueoka, Mitsune Tanimoto |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 60
Issue 1
Pg. 1-6
(Jun 2007)
ISSN: 0344-5704 [Print] Germany |
PMID | 17393168
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Etoposide
- Irinotecan
- Doxorubicin
- Cyclophosphamide
- Cisplatin
- Camptothecin
|
Topics |
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Carcinoma, Small Cell
(drug therapy, pathology)
- Cisplatin
(administration & dosage, adverse effects, therapeutic use)
- Combined Modality Therapy
- Cranial Irradiation
(methods)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Diarrhea
(chemically induced)
- Dose-Response Relationship, Drug
- Doxorubicin
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Injections, Intravenous
- Irinotecan
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neutropenia
(chemically induced)
- Prospective Studies
- Survival Analysis
- Thrombocytopenia
(chemically induced)
- Treatment Outcome
|